50358-63-9

Basic information

• Product Name: 5-Bromoquinoxalin-6-amine
• Synonyms: 6-Amino-5-bromoquinoxaline ,98%;5-BroMoquinoxalin-6-aMine, 6-AMino-5-broMoquinoxaline;Brimonidine Related Compound (5-Bromo-6-Aminoquinoxaline);6-AMINO-5-BROMOQUINOXALINE;5-BROMO-6-QUINOXALINAMINE;5-bromoquinoxalin-6-amine;6-Amino-5-bromoquinoxaline 98%;5-Bromo-6-aminoquinoxaline
• CAS NO: 50358-63-9
• Molecular Formula: C₈H₆BrN₃
• Molecular Weight: 224.06
• EINECS: 1592732-453-0
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Quinolines, Isoquinolines & Quinoxalines;Halides;Quinolines, Isoquinolines & Quinoxalines;Chemical Amines;Amines
• Mol File: 50358-63-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 151-153°C
• Boiling Point: 367 °C at 760 mmHg
• Flash Point: 175.8 °C
• Appearance: yellow solid
• Density: 1.744 g/cm³
• Vapor Pressure: 1.4E-05mmHg at 25°C
• Refractive Index: 1.747
• Storage Temp.: Refrigerator
• PKA: 0.33±0.30(Predicted)
• CAS DataBase Reference: 5-Bromoquinoxalin-6-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromoquinoxalin-6-amine(50358-63-9)
• EPA Substance Registry System: 5-Bromoquinoxalin-6-amine(50358-63-9)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 50358-63-9(Hazardous Substances Data)

Usage

Description

5-Bromoquinoxalin-6-amine is an organic compound with the chemical formula C8H6BrN3. It is a yellow solid and is known to be a metabolite of Brimonidine, which is a medication used in the treatment of certain eye conditions.

Uses

Used in Pharmaceutical Industry:
5-Bromoquinoxalin-6-amine is used as an active pharmaceutical ingredient for the development of antiglaucoma agents, specifically in the formulation of brimonidine tartrate ophthalmic solution with a concentration of 0.15%. It helps in reducing intraocular pressure in the eyes, providing relief from glaucoma and other eye conditions characterized by high pressure within the eye.
Used in Research and Development:
As a metabolite of Brimonidine, 5-Bromoquinoxalin-6-amine may also be used in research and development for understanding the pharmacological effects, metabolism, and potential applications of Brimonidine and its derivatives in various medical fields. This can contribute to the discovery of new drugs and therapies for different health conditions.

InChI:InChI=1/C8H6BrN3/c9-7-5(10)1-2-6-8(7)12-4-3-11-6/h1-4H,10H2

Upstream product

• 6298-37-9 6-aminoquinoxaline 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 6639-87-8 6-nitroquinoxaline 

Relevant articles and documents

Preparation method of brimonidine intermediate

The invention belongs to the technical field of drug synthesis, and particularly relates to a preparation method of a brimonidine intermediate. The method for preparing the brimonidine intermediate comprises the following steps: by taking 6-amino quinoxaline as a raw material and HBr as a bromine source, carrying out oxidative bromination in the presence of O2 through the action of a copper catalyst to prepare the brimonidine intermediate 5-bromo-6-amino quinoxaline. The method provided by the invention has the advantages of cheap and easily available reaction raw materials, mild reaction conditions, simple operation process, high product yield, high purity and high atom utilization rate, and is more suitable for industrial production.

Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines

A series of 29 new quinoxalines was synthesized and evaluated in vitro against several parasites (Leishmania donovani, Trypanosoma brucei brucei, and Trichomonas vaginalis). Several of them displayed interesting activities, and particularly four quinoxaline amides showed in vitro antileishmanial properties (IC50 less than 20 μM).

Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R1and R2each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R3, R4and R5each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.